GLP-1 weight loss for non-diabetic adults is now FDA approved through two medications: Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Both are sanctioned for adults with a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity. Trial data show meaningful, sustained weight loss when paired with lifestyle change.
FDA-Approved GLP-1 Options for Non-Diabetic Weight Loss
Two GLP-1-class drugs carry an FDA chronic-weight-management indication for adults without diabetes:
- Wegovy (semaglutide 2.4 mg weekly) – approved June 2021
- Zepbound (tirzepatide 5-15 mg weekly) – approved November 2023; tirzepatide is technically a dual GIP/GLP-1 agonist but is widely grouped with GLP-1 therapies
Other GLP-1 medications such as Ozempic, Mounjaro, Trulicity, and Victoza are approved for type 2 diabetes only and are not labeled for weight loss in non-diabetic adults, though prescribers sometimes use them off-label.
Eligibility for GLP-1 Weight Loss in Non-Diabetic Adults
The FDA criteria for Wegovy and Zepbound mirror each other:
- BMI 30 or higher (obesity), or
- BMI 27 or higher (overweight) plus at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
Wegovy is also approved for pediatric patients aged 12 and older with obesity. Zepbound expanded its label in 2024 to include moderate-to-severe obstructive sleep apnea in adults with obesity.
What the STEP and SURMOUNT Trials Show
The clinical evidence base is large and well documented in the New England Journal of Medicine.
STEP 1 (Semaglutide)
STEP 1 randomized 1,961 non-diabetic adults with overweight or obesity to weekly semaglutide 2.4 mg or placebo for 68 weeks. Mean weight loss was 14.9% on semaglutide vs. 2.4% on placebo. Roughly one-third of semaglutide participants lost 20% or more of their starting weight.
SURMOUNT-1 (Tirzepatide)
SURMOUNT-1 randomized 2,539 non-diabetic adults with obesity to weekly tirzepatide 5, 10, or 15 mg or placebo for 72 weeks. Mean weight loss was 15.0%, 19.5%, and 20.9% on the three tirzepatide doses vs. 3.1% on placebo. About 57% of those on the 15 mg dose lost 20% or more.
| Trial | Drug / Dose | Average Weight Loss | Duration |
|---|---|---|---|
| STEP 1 | Semaglutide 2.4 mg | 14.9% | 68 weeks |
| SURMOUNT-1 | Tirzepatide 5 mg | 15.0% | 72 weeks |
| SURMOUNT-1 | Tirzepatide 10 mg | 19.5% | 72 weeks |
| SURMOUNT-1 | Tirzepatide 15 mg | 20.9% | 72 weeks |
Side Effects and Safety in Non-Diabetic Users
Side-effect profiles in non-diabetic users mirror those in diabetic users. The most common are nausea, vomiting, diarrhea, constipation, and abdominal pain, mostly during dose escalation. Less common but serious risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and the boxed warning for thyroid C-cell tumors. People with personal or family history of medullary thyroid cancer or MEN 2 should not use these medications.
Off-Label Use in Adults Below the BMI Threshold
Use of GLP-1 medications in non-diabetic adults with BMI under 27 is off-label. Risks of off-label use include unclear long-term benefit, potential for excessive lean-mass loss, lack of insurance coverage, and possible nutritional concerns. The American Association of Clinical Endocrinology and obesity-medicine specialists generally discourage cosmetic use in adults at healthy weight.
Lifestyle Still Matters
All GLP-1 trials paired the medication with lifestyle counseling. Patients who maintained dietary and exercise changes generally retained more weight loss long term. For an evidence-based lifestyle foundation, see our guides to prediabetes-friendly nutrition and comprehensive treatment options.
What Happens If You Stop
The STEP 1 extension trial found participants regained roughly two-thirds of lost weight within a year of stopping semaglutide. SURMOUNT-4 showed similar regain after discontinuing tirzepatide. Most clinicians now treat obesity like hypertension: the medication works while you take it, and stopping usually leads to a return toward the original weight set point.
The Bottom Line
GLP-1 weight loss for non-diabetic adults is supported by strong randomized trial evidence when used within FDA criteria. Wegovy and Zepbound are the two approved options. The therapy is most effective when paired with sustained lifestyle change and continued long term. Talk with your clinician about your BMI, comorbidities, and goals before starting.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.
